☰

David W. Woessner, Ph.D. - Publications

Affiliations: 
Pharmacology and Toxicology University of Utah, Salt Lake City, UT 
Area:
Basal Ganglia Structure and Function
Tree Info Grants Similar researchers PubMed Report error

13 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Chang Y, Woessner DW, Lin W, Chen T, Xu B, Fan Y, Tan H, Peng J, Kasper L, Churchman ML, Gerhard DS, Loh ML, Hunger SP, Seth A, Gascoigne K, et al. Abstract IA12: Modeling and targeting CREBBP mutations in relapsed acute lymphoblastic leukemia Cancer Research. 78. DOI: 10.1158/1538-7445.Pedca17-Ia12  0.377
2015 Woessner DW, Eiring AM, Bruno BJ, Zabriskie MS, Reynolds KR, Miller GD, O'Hare T, Deininger MW, Lim CS. A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia. Leukemia. PMID 25721898 DOI: 10.1038/Leu.2015.53  0.522
2013 Miller GD, Woessner DW, Sirch MJ, Lim CS. Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML. Molecular Pharmaceutics. 10: 3475-83. PMID 23915432 DOI: 10.1021/Mp400323C  0.474
2013 Woessner DW, Lim CS. Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation. Molecular Pharmaceutics. 10: 270-7. PMID 23211037 DOI: 10.1021/Mp300405N  0.514
2013 Miller GD, Woessner DW, Lim CS. Abstract 2170: Development of a "dual-hit" combination therapy for CML. Cancer Research. 73: 2170-2170. DOI: 10.1158/1538-7445.Am2013-2170  0.538
2012 Constance JE, Woessner DW, Matissek KJ, Mossalam M, Lim CS. Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib. Molecular Pharmaceutics. 9: 3318-29. PMID 22957899 DOI: 10.1021/Mp3003539  0.416
2012 Dixon AS, Miller GD, Bruno BJ, Constance JE, Woessner DW, Fidler TP, Robertson JC, Cheatham TE, Lim CS. Correction to "improved coiled-coil design enhances interaction with bcr-abl and induces apoptosis". Molecular Pharmaceutics. 9: 1535. PMID 22444272 DOI: 10.1021/Mp300089A  0.315
2012 Dixon AS, Miller GD, Bruno BJ, Constance JE, Woessner DW, Fidler TP, Robertson JC, Cheatham TE, Lim CS. Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis. Molecular Pharmaceutics. 9: 187-95. PMID 22136227 DOI: 10.1021/Mp200461S  0.503
2012 Woessner DW, Lim CS. Abstract 5615: Combination therapy for chronic myelogenous leukemia: Targeting the BCR-ABL coiled-coil domain and other pathways for synthetic lethality Cancer Research. 72: 5615-5615. DOI: 10.1158/1538-7445.Am2012-5615  0.417
2011 Woessner DW, Lim CS, Deininger MW. Development of an effective therapy for chronic myelogenous leukemia. Cancer Journal (Sudbury, Mass.). 17: 477-86. PMID 22157291 DOI: 10.1097/Ppo.0B013E318237E5B7  0.436
2011 Dixon AS, Pendley SS, Bruno BJ, Woessner DW, Shimpi AA, Cheatham TE, Lim CS. Disruption of Bcr-Abl coiled coil oligomerization by design. The Journal of Biological Chemistry. 286: 27751-60. PMID 21659527 DOI: 10.1074/Jbc.M111.264903  0.484
2011 Woessner DW, Dixon AS, Lim CS. Abstract 1780: Potentiating chronic myeloid leukaemia treatment using oligomeric disruption and RNAi Cancer Research. 71: 1780-1780. DOI: 10.1158/1538-7445.Am2011-1780  0.503
2010 Moos PJ, Chung K, Woessner D, Honeggar M, Cutler NS, Veranth JM. ZnO particulate matter requires cell contact for toxicity in human colon cancer cells. Chemical Research in Toxicology. 23: 733-9. PMID 20155942 DOI: 10.1021/Tx900203V  0.314
Show low-probability matches.